Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ModernaTX, Inc.
Age
18–50
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female ≥ 18 and ≤ 50 years of age
Weight of 50 to 100 kg, inclusive
In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening
Has access to consistent and reliable means of contact and agrees to stay in contact with the study site for the duration of the study
You may not be if
Any acute or chronic clinically significant disease, as determined by physical examination or laboratory screening tests
Elevated liver function tests or safety laboratory test results
Positive screening test for the presence of anti-CHIKV IgG
Administration of another investigational study involving any investigational product within 60 days or 5 half-lives, whichever is longer
Has received any live attenuated or inactive vaccines within 4 weeks prior to check-in, or plans to receive any vaccine during the study
Known or suspected immune-mediated disease or immunosuppressive condition (including lymphoproliferative disorders)
Any neurologic disorder
History of idiopathic urticaria
Any bleeding disorder that is considered a contraindication to study drug infusion or blood collection
Receipt of immunoglobulins, a monoclonal antibody or any blood products within the preceding 6 months
Any acute illness at the time of enrollment
A positive test result for drugs of abuse
A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2 antibodies
A history of active cancer (malignancy) in the last 3 years
Donation of ≥ 450 mL blood or blood products within 30 days of study drug infusion
Clareo Health | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
